bluuebunny/crossref_metadata_2025 huggingface dataset:
P2278Risk of life-threatening ventricular tachyarrhythmia events in diabetes patients with higher ejection fraction in MADIT-CRT
Authors: Kutyifa V , Solomon S , McNitt S , Zareba W , Goldenberg I
Published: October 2019

Background

Data on the risk of life-threatening ventricular tachyarrhythmia events in diabetes patients with mild heart failure (HF) and higher ejection fraction (LVEF) are not currently known.

Objective

We aimed to assess the risk of life-threatening ventricular tachyarrhythmia events in mild HF patients with diabetes in patients with baseline LVEF ≤30% or >30%.

Methods

We evaluated the risk of life-threatening VT/VF treated with shock in mild HF patients with diabetes, by those with LVEF ≤30% or >30%, enrolled in MADIT-CRT. Kaplan-Meier analysis and multivariate adjusted Cox regression models were utilized.

Results

Out of 542 mild HF patients with diabetes and VT/VF data, 206 (38%) had LVEF >30% and 336 (62%) had LVEF ≤30%. The 5-year cumulative probability of VT/VF treated with shock was 15% in patients with diabetes LVEF >30% as compared to the 15% probability in patients with diabetes and LVEF ≤30% (p=0.342 for the overall difference in event rates during follow-up) (Figure). In Cox models, the risk of VT/VF treated with shock was similar in diabetes patients with LVEF>30% and LVEF ≤30% (HR=0.88, 95% CI= 0.51–1.53, p=0.647) after adjustment for age, ischemic etiology, prior ventricular or atrial arrhythmia, and CRT-D-LBBB interaction. The risk of VT/VF treated with shock was similar regardless of LVEF in both CRT-D patients (HR=1.09, p=0.830) and ICD only patients (HR=0.67, p=0.345).

Conclusion

Diabetes patients with an LVEF >30% are at similarly high risk of life-threatening ventricular tachyarrhythmias to patients with LVEF≤30%. Our findings highlight the need for further investigation and treatment of this uniquely high-risk patient cohort with a higher ejection fraction.

Acknowledgement/Funding

MADIT-CRT was funded by an unrestricted research grant from Boston Scientific to the University of Rochester.
P2281Inadequate heart rate control begets sustained ventricular arrhythmias in a large cohort of women
Authors: Erath J W , Kutyifa V , Assmus B , Burch A , Bondermann D , Russo A
Published: October 2019

Background

The Wearable Cardioverter Defibrillator (WCD) is an effective therapy for treating ventricular arrhythmias (VT/VF) in at-risk patients, while providing continuous heart rate (HR) monitoring. Because women are under-represented in defibrillator trials, we chose to specifically focus on HR control in women prior to VT/VF events.

Purpose

To evaluate HR profiles preceding sustained VT/VF in women fitted with a WCD.

Methods

Data from women fitted with WCD (≥30 days use) from 2015 to 2018 were obtained from the manufacturer's database. HR is expressed as a weekly resting nighttime median (midnight to 7 am). Men (random sample) with the same inclusion criteria served as a control.

Results

A total of 21,440 women, age 67±15 years, were included for analysis. Over a median WCD use of 90 days (59–116 days), 118 women (0.6%) and 133 men (0.8%) received shocks for VT/VF (p=0.01). Resting HR one-week preceding VT/VF was above the target of 70bpm in 55% of shocked women (65 of 118) versus 44% of non-shocked women (9,272 of 21,322, p=0.01) (figure). HR one week before WCD shock was similar in women and men (71 bpm vs. 72 bpm; p=0.60). Younger women (≤50 years) had higher HR prior to shock than older women (HR 80 bpm vs. 70 bpm p=0.003). Among shocked patients, 24-hour-survival was 89% in women and 88% in men. During three-month follow-up, the same percentage of men and women died after receiving adequate WCD shock therapy (18%).

Heart rate profiles

Conclusions

Women with adequate heart rate control experienced significantly less spontaneous VT/VF than those with higher heart rates. The WCD can be utilized as a diagnostic tool to monitor HR in at-risk women in addition to treating sustained VT/VF.
P2426Validating the diagnostic value of a machine learning algorithm for STEMI detection
Authors: Mehta S , Botelho R , Fernandez F , Villagran C , Frauenfelder A , Matheus C , Vieira D , Torres M A , Pinto G , Mazzini J , Pisana L , Jacobucci R , Marin M A , Funatsu C , Vallenilla I
Published: October 2019

Background

We have previously reported the use of Artificial Intelligence (AI) guided EKG analysis for detection of ST-Elevation Myocardial Infarction (STEMI). To demonstrate the diagnostic value of our algorithm, we compared AI predictions with reports that were confirmed as STEMI.

Purpose

To demonstrate the absolute proficiency of AI for detecting STEMI in a standard12-lead EKG.

Methods

An observational, retrospective, case-control study. Sample: 5,087 EKG records, including 2,543 confirmed STEMI cases obtained via feedback from health centers following appropriate patient management (thrombolysis, primary Percutaneous Coronary Intervention (PCI), pharmacoinvasive therapy or coronary artery bypass surgery). Records excluded patient and medical information. The sample was derived from the International Telemedical Systems (ITMS) database. LUMENGT-AI Algorithm was employed. Preprocessing: detection of QRS complexes by wavelet system, segmentation of each EKG into individual heartbeats (53,667 total beats) with fixed window of 0.4s to the left and 0.9s to the right of main QRS; Classification: A 1-D convolutional neural network was implemented, “STEMI” and “Not-STEMI” classes were considered for each heartbeat, individual probabilities were aggregated to generate the final label for each record. Training & Testing: 90% and 10% of the sample were used, respectively. Experiments: Intel PC i7 8750H processor at 2.21GHz, 16GB RAM, Windows 10 OS with NVIDIA GTX 1070 GPU, 8GB RAM.

Results

The model yielded an accuracy of 97.2%, a sensitivity of 95.8%, and a specificity of 98.5%.

Conclusion(s)

Our AI-based algorithm can reliably diagnose STEMI and will preclude the role of a cardiologist for screening and diagnosis, especially in the pre-hospital setting.
P2429More precise assessment of flow-mediated dilation by measuring individually determined maximum dilatory peak time in healthy middle-aged subjects and patients with diabetes mellitus type 2
Authors: Herbrand T , Coester H V , De Vries H , Heiss C , Heise T , Kelm M , Sansone R
Published: October 2019

The assessment of flow-mediated dilation (FMD) is widely used in clinical research to quantify endothelial function. FMD is calculated by subtracting the artery's baseline diameter from the peak diameter during hyperemia. However, there is no consensus on how to determine peak diameter. Many authors report FMD results based on values assessed at predefined time points. This may limit the accuracy and reproducibility of FMD. We hypothesised that FMD values using maximum dilatory peak time (MDP) would differ from those using predefined time points. Using individually determined MDP may lead to a lower number of subjects needed to show significance for a given difference in FMD.

FMD was measured in middle-aged subjects with and without diabetes mellitus type 2 (T2DM) by ultrasound (12-MHz transducer). In a subset of subjects, FMD was measured again 30 days later. All measurements were performed by certified research physicians and evaluated using appropriate software. FMD values were compared at 60 s and 90 s after start of hyperaemia and at MDP during hyperaemia.

FMD was measured in 100 healthy subjects and 72 subjects with T2DM (mean ± SD age 57±6 years, healthy: body mass index 26.2±3 kg/m2, blood pressure 127±10 /80±7 mmHg, DMT2: body mass index 29±3 kg/m2, blood pressure 135±11 / 86±5 mmHg, HbA1c 7.1±0.7%). FMD in healthy subjects was lower at predefined time points compared to MDP (least square mean difference (95% CI)) 60 s vs. MDP −1.14% (−1.72 to −0.56; p<0.0001) and 90 s vs. MDP −1.87% (−2.48 to −1.26; p<0.0001). Also in subjects with DMT2, FMD at predefined time points was lower compared to MDP (least square mean difference (95% CI)) 60 s vs. MDP −1.08% (−1.71 to −0.44; p<0.001) and 90 s vs. MDP −1.73% (−2.38 to −1.06; p<0.001). The intra-subject variability was lowest for MDP compared to 60 s and 90 s (15% vs. 36% and 51%, respectively). Assuming 80% power and alpha at 0.05, the individually determined peak requires 15 people to detect a 1% difference in FMD versus 26 subjects if determined at 60 s and 31 subjects if determined at 90 s.

This study demonstrated significantly higher FMD values and superior reproducibility of the individually determined maximum dilatory peak compared to peaks at predefined time points in healthy middle-aged people and patients with type 2 diabetes. This roughly halves the number of study participants needed to detect a 1% difference in FMD.
P2441The prognostic value of left atrial dyssynchrony in the general population
Authors: Hoeegholm Karsum E , Andersen D M , Modin D , Biering-Soerensen S R , Moegelvang R , Jensen G , Schnohr P , Gislason G , Biering-Soerensen T
Published: October 2019

Introduction

Parameters derived from left atrial (LA) speckle tracking such as LA peak reservoir strain and LA dyssynchrony are potent predictors of cardiovascular morbidity and mortality in various patient populations. However, whether LA dyssynchrony as evaluated by speckle tracking is associated with long-term outcome in the general population is currently unknown.

Methods

In a cohort study with participants from the general population 385 participants without atrial fibrillation (AF), ischemic heart disease (IHD), heart failure (HF) or previous ischemic stroke (IS) had a health examination and an echocardiogram, including LA speckle tracking, performed. LA dyssynchrony was defined as the standard deviation of the time to peak regional atrial reservoir strain values. The endpoints were all-cause mortality, a combined endpoint of AF and IS, and a combined endpoint of major adverse cardiovascular events (MACE) comprised of acute myocardial infarction (AMI), HF or cardiovascular death (CVD).

Results

Median LA dyssynchrony was 42 ms (IQR: 22–58 ms), 60% percent of included participants were women, mean age was 55 years (SD 16 years), 34% had hypertension and 7% had diabetes mellitus. During a median follow up of 16.1 years (IQR 15.0–16.3 years), 83 (22%) participants died, 60 (15%) reached the composite endpoint of AF and IS, and 38 (10%) reached the composite MACE endpoint.

Increasing LA dyssynchrony was associated with increasing age, lower estimated glomerular filtration rate, lower E/A ratio, lower e' and higher E/e'. In a univariable Cox regression, LA dyssynchrony was a significant predictor of all-cause mortality (HR 1.07, 95% CI 1.02–1.11, p=0.001, per 10 ms increase) but was not significantly associated with the combined endpoint of AF and IS (HR 1.05, 95% CI 1.00–1.10, p=0.064, per 10 ms increase) nor MACE (HR 1.04, 95% CI 0.98–1.12, p=0.22, per 10 ms increase). However, when adjusted for age, LA dyssynchrony did not predict all-cause mortality (HR 1.03, p=0.28), the combined endpoint of AF and IS (HR 1.01, p=0.83), or MACE (HR 0.99, p=0.88,). Similarly, after further adjustment for age, sex, smoking status, systolic blood pressure and cholesterol, LA dyssynchrony did not predict any of the study outcomes (All-cause mortality: HR 1.01, p=0.72) (AF and IS: HR 0.98, p=0.88) (MACE: HR 1.00, p=0.93).

Conclusion

In this general population study, LA dyssynchrony was not an independent predictor of all-cause mortality and did not predict MACE nor a composite outcome consisting of AF and IS.
P2444Comparison of 3D and 2D echocardiography-derived indices of left ventricular function and structure to predict long-term mortality in the general population: Southall And Brent Revisited (SABRE) study
Authors: Al Saikhan L , Park C , Tillin T , Williams S , Mayet J , Chaturvedi N , Hughes A
Published: October 2019

Background

Three-dimensional echocardiography (3DE) may have advantages over two-dimensional echocardiography (2DE) for the assessment of left ventricular (LV) function and structure. However, studies comparing 3DE and 2DE-derived indices in relation to mortality are limited, particularly in the general population.

Purpose

We examined associations between 2DE and 3DE-derived LV ejection fractions (LVEF) and volumes for all-cause mortality in a population-based sample.

Methods

A total of 899 individuals (age, 69.6±6.1 years; 77.5%male) from the SABRE study, a UK-based tri-ethnic community cohort, underwent a comprehensive transthoracic echocardiography examination. 2D LVEF and volumes were calculated, and full-volume 3D LV datasets acquired over 4 sub-volumes were obtained using a matrix-array transducer and were analysed offline using Qlab advanced, v7.0. The associations between both 2D- and 3D-derived LVEF (≥55% vs. <55%), body surface area indexed end-diastolic volume (iEDV) and end-systolic volume (iESV), and all-cause mortality were determined using Cox proportional hazards models. Survival curves were constructed using the Kaplan-Meier method.

Results

Of the 899 individuals, 118 (13.1%) died over a median follow-up period of 8 years to 2018. Kaplan Meier survival estimates (Figure 1 illustrates LVEF) and Cox regression revealed that 2D and 3D LVEF, iEDV and iESV were associated with increased risk of all-cause mortality (LVEF (≥55% vs. <55%), 3DE: HR=0.53 (0.35, 0.80); 2DE: HR=0.51 (0.34, 0.75), iEDV (per 1SD increment), 3DE: HR=1.20 (1.0, 1.41); 2DE: HR=1.19 (1.0–1.41), iESV (per 1SD increment), 3DE: HR=1.27 (1.1, 1.52), 2DE: HR=1.32 (1.15, 0.1.51)). However, 3DE associations tended to be stronger in models adjusted for classical risk factors including age, sex, ethnicity, systolic blood pressure, cholesterol:HDL ratio, body mass index, antihypertensive medications, diabetes, and smoking (LVEF (≥55% vs. <55%), 3DE: HR=0.59 (0.39, 0.90); 2DE: HR=0.69 (0.46, 1.0), iEDV (per 1SD increment), 3DE: HR=1.20 (1.0, 1.41); 2DE: HR=1.10 (0.93, 1.31), iESV (per 1SD increment), 3DE: HR=1.27 (1.1, 1.52), 2DE: HR=1.20 (1.04, 0.1.39)).

Figure 1. Kaplan-Meier curves.

Conclusions

In this population-based study, both 2DE and 3DE-derived indices of LV structure and function were associated with all-cause mortality independently of classical risk factors, with some indication that strengths of association were greater for 3DE-derived indices.

Acknowledgement/Funding

SABRE is funded by BHF, Diabetes UK, the MRC and the Wellcome Trust. LA holds a scholarship grant from Imam Abdulrahman Bin Faisal University, SA
P2452Application of left atrial strain for differentiation between pre- and post-capillary pulmonary hypertension
Authors: Inoue K , Remme E W , Khan F H , Andersen O S , Gude E , Skulstad H , Smiseth O A
Published: October 2019

Background

Pulmonary hypertension (PH) is classified as pre- or post-capillary PH, and pulmonary capillary wedge pressure (PCWP) >15 mmHg is used as criterion for post-capillary PH. Elevated left atrial (LA) pressure is associated with reduced LA reservoir strain. Thus, LA strain may potentially serve to differentiate between these diagnoses.

Objectives

This study tested the hypothesis that LA strain can be used as a noninvasive parameter to differentiate between pre- and post-capillary PH.

Methods

We analyzed 103 patients (mean age: 58 years, 51 female) referred to right heart catheterization due to unexplained dyspnea or suspected heart failure. Echocardiography was performed within 24 hours of the invasive procedure. Mean pulmonary artery pressure (PAP) was noninvasively estimated from tricuspid regurgitation (TR) velocity and inferior vena cava (IVC) diameter and collapsibility. LA reservoir strain was calculated from apical four-chamber view by speckle tracking echocardiography, and was feasible in 101 patients.

Results

Twenty-eight patients were invasively confirmed with pre-capillary PH and 43 patients with post-capillary PH. The remaining 32 patients had no PH. LA reservoir strain was significantly lower in patients with post-capillary PH than patients with pre-capillary PH (9.9±5.5% vs. 24.6±8.2%, p<0.01). At a cut-off value of 15.4%, LA reservoir strain could predict elevated PCWP >15 mmHg with AUC=0.88, sensitivity=84.8% and specificity=81.8%. As shown in the figure, echocardiography with LA reservoir strain correctly differentiated 82% of patients into pre- and post-capillary PH.

Conclusions

These results suggest that LA reservoir strain can be used to predict elevated PCWP, thus allowing discrimination between pre- and post-capillary PH.
P2455Global peak left atrial longitudinal strain - a good predictor of left atrial appendage thrombus in patients in sinus rhythm with heart failure and very low left ventricular ejection fraction
Authors: Zandecki L , Kurzawski J , Janion-Sadowska A , Sadowski M
Published: October 2019

The aim of this study was to determine if various clinical and transthoracic echocardiography data including left atrial strain analysis could predict the presence of left atrial appendage thrombus (LAAT) in heart failure (HF) patients with very low left ventricular ejection fraction (LVEF), sinus rhythm at presentation and no history of atrial fibrillation or any other established indication for anticoagulation.

Material and methods

Sixty-seven patients with HF, LVEF <25%, sinus rhythm and not anticoagulated were included. Transesophageal echocardiography was performed in all patients to allow detection of LAAT.

Results

LAAT was found in 21 (31.3%) patients. Global peak left atrial longitudinal strain (PALS) was the best predictor of LAAT presence in univariate logistic regression analysis (Gini index 0.65, AUC 0.83) – data for other variables are presented in the Table 1. In the multivariate model after the inclusion of global PALS no other available variable could significantly improve it. The global PALS value of 8% was a good discriminator of LAAT presence with OR 26.2 (95% CI 6.8–103) if global PALS was <8% at p<0.001.

Table 1. Univariable models for potential risk factors for LAAT incidence in the study population OR (95% CI) p-value Gini index Age 1.01 (0.96–1.06) 0.71 0.02 Heart rate 0.99 (0.94–1.03) 0.57 0 Body surface area 0.66 (0.03–12.45) 0.78 0.03 Ischaemic HF etiology 2.11 (0.73–6.07) 0.17 0.18 Hypertension 1.10 (0.39–3.09) 0.86 0.02 Diabetes 0.59 (0.18–1.89) 0.37 0.11 Chronic kidney disease 1.29 (0.46–3.65) 0.63 0.06 Prior stroke or TIA (transient ischemic attack) 1.75 (0.35–8.63) 0.49 0.06 LA diameter 0.96 (0.3–3.03) 0.94 0.02 LAVI (LA volume index) 1.06 (1.01–1.11) 0.01 0.46 LVEF 0.99 (0.87–1.12) 0.88 0.07 E/A 1.28 (0.79–2.09) 0.31 0.1 E/e' 0.98 (0.91–1.04) 0.44 0.15 Global PALS 0.43 (0.29–0.64) <0.001 0.65 Global PACS (peak atrial contraction strain) 1.42 (0.91–2.21) 0.13 0.27

Conclusions

LAAT has been a relatively common finding in this group of HF patients and PALS has shown prognostic potential in LAAT identification.
P2465Assessment of left atrial electro-mechanical delay to predict atrial fibrillation in hypertrophic cardiomyopathy
Authors: Tjahjadi C , Hiemstra Y L , Van Der Bijl P , Pio S M , Marsan N A , Delgado V , Bax J J
Published: October 2019

Background

Left atrial remodelling in hypertrophic cardiomyopathy (HCM) is recognized as the main contributor to the development of atrial fibrillation (AF). It is well reported that the occurrence of AF in HCM increases both morbidity and mortality. Therefore, early recognition of AF is essential. Due to its often silent and paroxysmal nature, the diagnosis can be missed.

Purpose

PA-TDI, representing total atrial conduction time, reflects the left atrial structural and electrical remodelling. We sought to evaluate the association between this novel non-invasive echocardiographic parameter and AF in patients with HCM.

Methods

The electronic charts of patients with HCM and no previous history of AF from 1993 to 2018 were retrospectively analysed. PA-TDI was measured offline using pulsed wave tissue Doppler imaging with the sample volume placed on the lateral wall of the left atrium just above the mitral annulus in an apical 4-chamber view. The time interval was determined from the onset of P wave on surface ECG to the peak of the a' wave of the left atrial tissue Doppler tracing.

Results

There were 208 patients (64% male) with a mean age of 53±14 years in this study. The incidence of AF was 20% over a median follow-up of 56.3 (IQR 18.4–84.5) months. Patients who developed AF, had higher baseline PA-TDI intervals when in sinus rhythm (134±23 ms vs 111±30 ms, P<0.001) than those who remained free from AF. The cut-off value of PA-TDI duration was the median at 115 ms. A PA-TDI ≥115 ms was independently associated with new onset AF (HR: 2.5, 95% CI: 1.1–5.5, P=0.02) after correcting for age, left atrial diameter and E/e'.

Conclusion

A prolonged PA-TDI was strongly associated with the development of AF in patients with HCM. This parameter may be useful to risk-stratify patients with HCM who are at risk of having AF.
P2471Adaptation of ventricular function the first year after heart transplantation assessed with echocardiography
Authors: Ingvarsson A , Werther Evaldsson A , Radegran G , Waktare J , Smith J G , Roijer A , Meurling C
Published: October 2019

Background/Introduction

Echocardiography is commonly used in evaluation patients after heart transplantation (HTx). Detecting discrete changes in ventricular function is important but challenging using standard echocardiographic parameters. Furthermore, interpretation of findings are complicated by the fact that data on early possible adaptation is sparse.

Purpose

We sought to detect alterations in biventricular function primarily using speckle tracking derived strain at four time-points during the first year post HTx.

Methods

Fifty HTx patients (40 males, mean age 50±12 years) were prospectively included. Patients were examined 1, 3, 6 and 12 months after HTx using an iE33 platform with a S5–1 transducer and strain analysis was performed offline with a dedicated software: CMQ, Q-lab 10.3 (Philips Healthcare, Eindhoven, NL). Values were compared using paired t-test and expressed as mean±SD, 95% CI.

Results

Regarding left ventricular (LV) parameters no difference were detected between 1 and 12 months. LV ejection fraction (EF) was 58±5% vs. 58±7%, global longitudinal strain (GLS) was −15±5% vs. −16±4% and global circumferential strain (GCS) was −22±7% vs. −21±6% respectively. Conventional parameters of right ventricular (RV) function: Tricuspid annular plane systolic excursion (TAPSE) improved from 12±2 mm at 1 month to 15±5 mm (p<0.01) at 12 months and tricuspid annular systolic velocity (S') improved from 8.1±1.9 cm/s to 9.5±2.7 cm/s (p<0.01) at 12 months. Fractional area change (FAC) remained unaltered. Strain measurements of RV function improved gradually between 1 and 12 months. RV GLS was −15±3% vs. −17±3% (p<0.01) and strain for the RV lateral wall (RVfree) was −15±3% vs. −18±3% (p<0.001) respectively. Progressive improvement in RV strain is illustrated in Fig 1.

Right ventricular strain post HTx

Conclusion

Our data indicate that clinically stable HTx recipients have reached steady state regarding LV function already 1 month after transplantation. This suggests that alterations in LV function parameters after this time-point can be used to detect adverse events.

On the contrary, right ventricular longitudinal function show significant gradual improvement during the first year following HTx indicating that the RV adaptation-process is extended in comparison to the LV.

We found that measurements of LV function at 1 month and RV function at 12 months post HTx are comparable to previously published normal values in clinically stable HTx patients. Nevertheless, further studies addressing possible continuous improvement in RV function beyond 1 year post HTx would be of interest.
P2480Sub-optimal anti-diabetic treatment in patients with pre-existing and newly diagnosed diabetes admitted for acute myocardial infarction. A study from the FAST-MI 2015 registry
Authors: Schiele F , Puymirat E , Ferrieres J , Simon T , Danchin N
Published: October 2019

Background

In patients (pts) with Acute Myocardial Infarction (AMI), we evaluate how diabetes is detected and treated at discharge.

Methods

Using the French FAST-MI 2015 registry, pts were classed as non-diabetic (NonDiab), pre-existing (PreEx) or newly diagnosed (NewDiab) diabetes. PreEx was defined by history or pretreatment; NewDiab as no history, no anti-diabetic treatment plus HbA1C>6.5% or admission glucose ≥200mg/dL. Characteristics and adjusted 1-year mortality were compared.

Results

In 5291 FAST MI pts, 3857 (73%) were NonDiab, 1145 (21.5%) PreEx and 289 (5.5%) NewDiab (176 had glucose ≥200mg/dL; 143 had HbA1C >6.5%). PreEx pts were older, had more comorbidities, and higher GRACE score vs NonDiab. NewDiab pts had higher HbA1C (8.9%±9.2 vs 5.65%±0.38 in NonDiab; 7.5%±2.2 in PreEx). At 1 yr, diabetic pts (PreEx and/or NewDiab) had a 2.5-times higher adjusted risk of death. At discharge, DAPT, statins, ACEi and betablockers were less often prescribed in PreEx vs NonDiab or NewDiab pts. In diabetic pts, vs admission, the number of anti-diabetic treatments decreased at discharge in 11%, no change in 69% and increased in 20%. Despite higher HbA1C in NewDiab vs PreEx pts, anti-diabetics were less often prescribed in NewDiab (23%) vs PreEx pts (75%) (table). In pts with HbA1C>8%, treatment intensification was observed in 30%.

Admission treatment Discharge treatment NonDiab PreEx NewDiab NonDiab PreEx NewDiab 3759 (71%) 1283 (24%) 249 (5%) 3759 (71%) 1283 (24%) 249 (5%) Any Anti Diabetic Tx 0 975 (76%) 0 51 (1%) 931 (75%) 53 (23%) Insulin 0 339 (26%) 0 2 404 (33%) 13 (6%) Biguanide 0 456 (36%) 0 2 412 (34%) 30 (13%) Sulfonylureas 0 258 (20%) 0 2 244 (20%) 4 DPP4i 0 175 (14%) 0 2 176 (14%) 6 (3%) GLP1 RAs 0 108 (8%) 0 1 117 (10%) 10 (1%) DAPT 3212 (88%) 1009 (90%) 201 (87%) Aspirin 778 (21%) 550 (45%) 66 (27%) 3533 (96%) 1170 (95%) 218 (94%) Statins 964 (25%) 721 (56%) 69 (28%) 2394 (92%) 1109 (82%) 216 (93%) ACEi/ARB 1028 (27%) 672 (53%) 69 (28%) 2744 (74%) 925 (75%) 174 (87%) Coronary Angiography 3684 (98%) 1202 (94%) 240 (96%) PCI 3010 (80%) 907 (71%) 201 (81%)

Conclusions

In AMI pts, 5.5% have previously unknown diabetes and have a higher risk of death, similar to that of pts with PreEx diabetes. Treatment initiation and intensification are sub-optimal.
P2481The effect of DPP-4i, GLP-1RA, SGLT-2i and long-acting insulin on platelet function in patients with type 2 diabetes mellitus
Authors: Stampouloglou P K , Antonopoulos A , Siasos G , Bletsa E , Batzias K , Paschou S A , Oikonomou E , Gouliopoulos N , Tsigkou V , Kassi E , Thanopoulou A , Vryonidou A , Tentolouris N , Pallantza Z , Tousoulis D
Published: October 2019

Background

Patients with type 2 diabetes mellitus (T2DM) are at higher risk for thrombotic events. Platelet function may be used to assess prothrombotic state in patients with cardiovascular disease.

Purpose

We aimed to investigate whether the administration of novel antidiabetic agents influence platelet function in TDM2 patients.

Patients and methods

We 60 enrolled consecutive patients with T2DM, on stable antidiabetic therapy, who did not achieve therapeutic targets. Subjects were assessed to receive an additional anti-diabetic agent; dipeptidyl peptidase-4 inhibitor (DPP4i, n=14), glucagon like peptide-1 receptor agonist (GLP1RA, n=24), sodium/glucose cotransporter-2 inhibitor (SGLT2i, n=22). Platelet reactivity was measured with PFA-200 collagen/epinephrine (c-EPI) and PFA-200 collagen/ADP (c-ADP) closure time. Glycosylated hemoglobin (HbA1c), c-EPI and c-ADP were assessed at baseline and 3 months after treatment intensification.

Results

There was no difference between the study groups regarding gender, age, hypertension, dyslipidemia, smoking, Hba1c and CADP or CEPI (p=NS for all) at baseline. All groups achieved better glycemic control in terms of HbA1c values between baseline and follow-up (for DPP4i: 7.4±0.2% vs 6.7±0.2%, for GLP1RA: 8.3±0.2% vs 6.9±0.1%, for SGLT2i: 7.5±0.1% vs 6.7±0.1% and for insulin 9.8±0.5% vs 7.7±0.4%, p<0.001 for all). After a 3 month-period, treatment intensification with these novel agents did not influence c-EPI and c-ADP values [155.4±6.64 sec vs 152.9±8.28 sec (p=0.678) and 106.6±4.30 sec vs 106.8±3.93 sec (p=0.955) respectively] in whole population. In subgroup analysis, for patients off antiplatelet treatment (n=31), c-EPI was significantly decreased from 148.4±8.5 to 129.8±13.9 sec (p=0.036), but not c-ADP (from 105.4±5.3 to 99.3±4.9 sec, p=0.094). In patients who did receive antiplatelets (n=37), c-EPI and c-ADP were not significantly changed (c-EPI 163.1±10.9 to 179.6±13.9 sec p=0.201 and c-ADP from 106.6±8.2 sec to 114.6±7.3 sec, p=0.318) respectively.

Conclusion

Antiplatelet treatment prevents thrombotic risk in T2DM patients receiving novel antidiabetics. The effects of novel antidiabetics on platelet reactivity -as well as any distinct class properties- merits further investigation.

Acknowledgement/Funding

None
P2487Echocardiography and NT-ProBNP both provide independent and improved prediction of prognosis in a type 1 diabetes population without heart disease and with preserved ejection fraction
Authors: Roerth R , Jorgensen P G , Andersen H U , Goetze J P , Rossing P , Jensen M T
Published: October 2019

Background

Cardiovascular disease is the most common comorbidity in type 1 diabetes (T1D). Current guidelines, however, do not include routine echocardiography or cardiac biomarkers in T1D.

Objectives

To investigate if echocardiography and NT-proBNP provide incremental prognostic information in individuals with T1D without heart disease and with preserved left ventricular ejection fraction (LVEF).

Methods

A prospective cohort of individuals with T1D without heart disease and with preserved LVEF (≥45%) from the outpatient clinic were included. Follow-up was performed through Danish national registers. The association between E/e', a marker of diastolic function, from echocardiography and NT-proBNP with major adverse cardiovascular events (MACE) was tested. MACE was defined as death from all-causes, acute coronary syndromes, cardiac revascularization, incident heart failure, or stroke. Additionally, the incremental prognostic value when adding E/e' and NT-proBNP to the clinical Steno T1D Risk Engine score (including age, sex, duration of diabetes, systolic blood pressure, LDL, HbA1c, presence of albuminuria (micro-or macroalbuminuria), eGFR, smoking status, and physical activity [low, medium, high]), was examined. Follow-up was 100% complete.

Results

Of 964 individuals (mean (SD)) age 49.7 (14.5) years, 51% men, HbA1c 66 (14) mmol/mol, BMI 25.6 (4.0) kg/m2, and diabetes duration 26.1 (14.5) years), 121 (12.6%) experienced MACE during 7.5 years of follow-up. In the full multivariable model, E/e' significantly and independently predicted MACE: (HR (95%)) E/'e <8 (n=639) vs. 8–12 (n=248): 2.00 (1.23; 3.25), p=0.005, E/'e <8 vs E/e'≥12 (n=77): 3.36 (1.8; 6.1), p<0.001. Also, NT-proBNP significantly predicted outcome: NT-proBNP <150 pg/ml (n=435) vs. 150–450 pg/ml (n=386): 1.52 (0.9; 2.5), p=0.11, NT-proBNP <150 pg/ml vs NT-proBNP >450 pg/ml (n=143): 2.78 (1.6; 4.9), p<0.001. Adding both (log)E/e' and (log)NT-proBNP to the Steno T1D Risk Engine score significantly and incrementally improved risk prediction: Harrell's C-index: Steno T1D Risk Engine (AUC 0.783 (0.747; 0.818)) vs. Steno T1D Risk Engine + (log)E/e' (AUC 0.805 (0.773; 0.837)): p<0.001 and Steno T1D Risk Engine + (log)E/e' + (log) NT-proBNP (AUC 0.816 (0.783; 0.848)): p=0.002. The risk of MACE by groups of E/e' and NT-proBNP is shown in the figure.

Figure 1

Conclusion

In individuals with T1D without heart disease and with preserved LVEF, E/e' and NT-proBNP significantly improved risk prediction of cardiovascular events beyond clinical risk factors alone. Echocardiography and NT-proBNP could have a role in clinical care.
P2489What are the main determinants of an increase in bnp level in asymptomatic diabetic patients without known cardiac disease?
Authors: Patin C , Vidal Trecan T , Dillinger J G , Paven E , Cohen Solal A , Logeart D , Riveline J P , Gautier J F , Henry P
Published: October 2019

Background

Diabetes mellitus is associated with a high risk of heart failure. The predictors of futures heart failure events in diabetic patients are not clearly understood. BNP measurement can be used as a surrogate endpoint for the diagnosis of heart failure. We investigated the determinants of an increase in BNP level in a large cohort of asymptomatic diabetic patients without known cardiac disease

Methods

This prospective study included consecutive stable diabetic (type 1 or 2) patients coming for yearly check-up between March 2015 and July 2018 in the university center for the study of diabetes and its complications. Patients with an history of cardiac disease (coronary artery disease, atrial fibrillation, cardiomyopathy, previous heart failure ...) were excluded. All patients had a complete clinical exam, blood pressure measurement (3 consecutive times – mean of 2 lasts measurements), ECG, and blood sample including HbA1C, risk factors assessment, renal function (CKD-EPI) and BNP measurement. Data are presented as mean±SD or median - Spearman's rank and multivariate regression were used for analysis.

Results

3743 patients (mean age 57±14 y.o. – 57% male – 78% / 18% / 4% of type 2, type 1 or other type of diabetes respectively – Mean duration of diabetes 17 [1–63] y. – 44% treated with insulin) were studied. Mean±SD / median [min-max] BNP level was 25±39 / 12 [4–737] ng/L. BNP was <20 / 21–35 / 36–50 / 51–100 / 101–400 / >400 ng/L in 69 / 15 / 6 / 7 / 3 / 0.1% of the population respectively. The parameters most correlated with BNP level in type 1 and type 2 diabetes were age, duration of diabetes, renal function, HbA1C, and pulsed pressure. For multivariate analysis, renal function was removed of the model as it was highly correlated with age (r=−0.68). Multivariate analysis demonstrated that in type 1 diabetes, high BNP level was linked to age (p<0.001), pulsed pressure (p<0.001), duration of diabetes (p=0.003) and HbA1C (p=0.02). In type 2 diabetes, high BNP level was linked to age (p<0.0001), pulsed pressure (p<0.0001), duration of diabetes (p=0.005) but not HbA1C (p=0.09). Interestingly the type of treatment (mainly insulin treatment) was not independently related to an increase in BNP level.

Conclusion

Age, pulsed pressure and duration of diabetes are the main determinants of an increased level of BNP in asymptomatic diabetic patients without any history of cardiac disease. This result could help to select a population who could benefit to a more extensive follow up concerning heart failure.
P2492The impact of diabetes mellitus newly diagnosed by glycated hemoglobin on outcomes in patients undergoing percutaneous coronary intervention - five years prospective follow up study
Authors: Abu Tailakh M , Friger M , Zahger D , Sidi A , Mazor-Dray E , Novack V
Published: October 2019

Background

Following percutaneous coronary interventions (PCI), both short and long terms ischemic outcomes are worse in patients with Diabetes Mellitus (DM) compared to those without DM.

Methods

We prospectively enrolled consecutive patients undergoing PCI. Glycated Hemoglobin (HbA1c) levels were assessed during the index hospitalization and newly diagnosed DM was defined as HbA1c≥6.5% in the absence of the previous diagnosis. The primary outcome was Major Adverse Cerebro and Cardiovascular Events (MACCE) defined as death, stroke, PCI or acute myocardial infarction at five years.

Results

Diabetes was previously diagnosed in 391 (34%) patients (DM group), 221 (19%) had newly diagnosed DM based on the HbA1c level and 539 (47%) did not have diabetes (Non-DM). In DM group HbA1c was 7.80±1.36% as compared with 7.62±1.30% in patients with newly diagnosed DM (p<0.001). These patients were younger (62.0±11.3 years) compared to DM (67.9±10.4 years) and non-DM (63.7±13.0) patients, p<0.001. five years MACCE rates were 37.8%, 65.5% and 42.5% in the non-DM, newly diagnosed DM and DM groups, respectively (p<0.001). Multivariate analysis showed that compared to non-DM, the adjusted two year hazard ratios for MACCE were 1.83 (p<0.001), 1.47 (p=0.01) and 0.52 (p=0.01) respectively in patients with known DM, newly diagnosed DM, and patients with newly diagnosis DM who had DM treatment started after PCI.

Conclusion

Newly diagnosed DM based on peri-procedural HbA1c is common and associated with increased short and long term risk for adverse outcomes. Our results show that the diagnosis and early treatment of diabetes in patients undergoing PCI should be included into the routine practice.
P2498Exercise capacity and all-cause mortality in remote Indigenous and non-Indigenous populations
Authors: Chang D D , Kangaharan N , Forde J , Goh D , Elangovan H , Manek N , Arauz C , Brady S , Sanders P , Wong C X
Published: October 2019

Background

Exercise capacity is a powerful predictor of all-cause mortality. However, its association with Indigenous populations in Central Australia, who face disproportionate health burdens, is unclear. Given the isolation from tertiary centers, exercise testing could provide useful local risk-stratification.

Purpose

To characterize the association of exercise capacity with all-cause mortality in Indigenous and non-Indigenous individuals in remote Central Australia.

Methods

Demographic, medication, and all-cause mortality data were prospectively collected from patients undergoing exercise stress tests from 2007–2017.

Results

A total of 3,414 patients (34% Indigenous) were included. At 4.8±2.9 years of follow-up, 86 (2.5%) deaths had occurred. Each 1-MET increase in exercise capacity conferred a 14% lower risk for mortality among Indigenous individuals (HR 0.86, 95% CI 0.79–0.94) and 20% lower risk for mortality among non-Indigenous individuals (HR 0.80, 95% CI 0.73–0.89) after adjusting for age, comorbidities, and medications. Mortality risk reduction for each 1-MET increase in exercise capacity was similar (p=0.32) for Indigenous and non-Indigenous individuals.

Conclusions

Exercise capacity is a significant predictor of all-cause mortality in Indigenous and non-Indigenous individuals. These findings have important clinical implications towards exercise capacity for risk-stratification and preventative importance of physical activity.
P2507Role of “Walk with a doc” program practice in total risk approach to prevention of cardiovascular disease in RF
Authors: Bockeria O L , Kudzoeva Z , Khugaev S G
Published: October 2019

Background

It is known that life-style related factors are the main risk factors for CVD morbidity and mortality. In countries with economies in transition (such as Russia) many efforts were aimed at CVD diagnostic and treatment procedures improvement, but lack of primary prevention strategies is observed in general population. CVD morbidity and mortality could be prevented through population based strategies.

Purpose

To evaluate the feasibility and potency of implementing “Walk with a doc” program practice using newly-developed “Cardiac numbers Diary” for estimation of the individual risk on making decision about whether to initiate specific preventive action to reduce CVD morbidity.

Methods

The program has successfully started in Moscow, RF in July 2012 as a Russian branch of the global “Walk with a doc” activity. As of January 2019 there are 1576 participants in the database. Special “Cardiac numbers Diary” was developed and includes special charts to allow the introduction of the total risk stratification approach for management of CVD. The charts use a modelling approach with age, sex, physical activity, smoking, blood pressure, body weight, blood glucose and cholesterol. With support of center specialists the weekly events are carried out in different open space grounds and include the assessment of the above risk factors, life style modifying counseling including lectures and 35–40 minutes' walk at the moderate pace. 150 participants participated in more than 20 walks mean age 58,2 years old (±17,1) were assessed in this prospective study. They were assessed for risk factors modifying in 6 months follow-up period. At the moment of inclusion 37.5% participants had arterial hypertension, 12.1% were smokers, 20.2% were overweight. The official Walk-with-a-doc movement is registered in RF. Special Web site provides information on future events, physician team, life-style, diet, physical activity recommendations, photo materials and etc.

Results

After 6 month of regular walking the number of hypertensive participants decreased to 20.2%. 9.4% of all participants were able to lose weight by 1–6 kg, and 33.3% quit smoking. 75% of people who walked noticed an increase in the level of physical activity. 17.3% of them underwent inpatient treatment using high-tech medical care. Ther were no major events in the above cohort of patients.

Conclusions

“Walk with a doc” program practice using newly-developed individual “Cardiac numbers Diary” for a predicted individual risk with regular professional counseling can be a useful guide for making clinical decisions on the intensity of preventive interventions to reduce cardiovascular risk factors in general population.

Acknowledgement/Funding

None
P2512Effects of two different preventive counselling programs with remote support on added sugar and refined carbohydrates intake pattern in coronary patients with abdominal obesity
Authors: Pogosova N , Salbieva A O , Sokolova O Y , Yufereva Y M , Ausheva A K , Karpova A V , Yusubova A I
Published: October 2019

Background

Restricting added sugar and refined carbohydrates is essential for a healthy diet, especially for overweight or obese patients (pts). Pts education has a potential to improve dietary patterns in coronary artery disease (CHD).

Purpose

To assess the impact of 2 preventive counselling programs with subsequent remote support resulted after hospitalization on salt intake in pts with CHD and obesity.

Methods

A prospective randomized parallel-group study in hospitalized nonsurgical pts with confirmed stable CHD and concomitant abdominal obesity. Most hospitalizations were due to elective percutaneous coronary intervention. Pts were randomized (1:1:1) into 3 groups. Before discharge, Groups 1 and 2 received comprehensive counselling with focus on diet followed by remote counselling by phone (Group 1) or via text messages (Group 2). Remote counselling was delivered weekly (Months 1–3) and then monthly (Months 4–6). Group 3 received standard advice only. Self-reported sugar/refined carbohydrates intake was assessed by consumption of added sugar, sugar-sweetened beverages and pastry.

Results

A total of 120 pts (mean age±SD, 57.75±6.25 years, men, 83.4%) were enrolled. The table presents self-reported dietary habits at baseline and at 12 months. At 1 year, significant improvements of relevant dietary habits vs control were seen in both intervention groups.

Group 1 Group 2 Group 3 (control) Group 1 vs 3, Group 2 vs 3, (n=40) (n=40) (n=40) P for change from baseline P for change from baseline Amount of sugar added per cup tea or coffee, teaspoons, mean ± SD   Baseline 2.65±0.77 2.45±0.81 2.48±0.72   At 12 months 2.08±0.83** 1.95±0.64** 2.47±0.69 <0.01 <0.01 Pts avoiding sugar-sweetened beverages, %   Baseline 37.50 32.50 25.00   At 12 months 92.50** 90.00** 13.16 <0.01 <0.01 Pts restricting pastry to no more than 1–2 times a week, %   Baseline 37.5% 47.5% 57.5   At 12 months 70.0%** 72.5%** 39.47 <0.01 <0.05 **p<0.01 vs baseline within group.

Conclusion

Pre-discharge preventive counselling with subsequent remote support in coronary patients with abdominal obesity resulted in significant improvement of dietary habits in terms of added sugar, sugar-sweetened beverages and pastry intake.
P2515Cardiac rehabilitation in patients with refractory angina: preliminary results
Authors: Dourado L , Assumpcao C R A A , Jordao C P , Vieira M L C , Gowdak L H W , Cesar L A M , Matos L D N J
Published: October 2019

Introduction

Refractory angina (RA) implies important impairment of quality of life. Cardiac rehabilitation (CR) is still not recommended by guidelines due to few evidence regarding its effects in this population. This study evaluated the impact of CR on physical performance and on angina/ischemia threshold.

Methods

36 RA patients undergoing optimal medical therapy were randomly assigned to a 12-week exercise based CR program or stablished clinical follow-up (CF). Clinical evaluation, exercise bicycle stress echocardiography (SE) and cardiopulmonary exercise testing (CP) were performed before and after the protocol. CR group performed in-hospital exercise sessions, and the aerobic training prescription was based on CP parameters or ischemia/ angina threshold. Each CR class was 60 min in duration (5min warm-up, 30min aerobic and 5min cooldown, 15min low load resistance training and 5min stretching). Bonferroni multiple comparison and t test were used in statistical analysis.

Results

Baseline characteristics didn't differ between groups. In RC group, 40% presented CCS 2, 25% CCS 3 and 35% CCS 4, while in CF group, 41%, 23.5% and 35.5%, respectively (p=0.5). There was no change in CCS between groups after intervention. CR group presented an increase in ischemic threshold in SE when compared to CF group (234.6±87.9s to 293.8±130.9 s vs. 200.9±78.6s to 203.7±93.7s, p=0.044), increase in angina threshold in SE (156.00±62.2s to 260.1±152.8s vs. 190.6±96.6s to 152.9±76, 7s, p=0.041) and increase in CP total duration (347.9±143.2s to 489.8±170.2s vs. 331.7±128.5s to 323.5±101.0s, p=0,016).

Baseline characteristics in both groups Variables CR group (n=19) CF group (n=17) p Male sex (%) 63.2 58.8 0.8 Age, years (mean ± SD) 61.2±8.7 62.9±8.8 0.6 LVEF, % (mean ± SD) 55.7±7.3 50.0±10.4 0.08 SBP, mmHg (mean ± SD) 125.6±18.0 122.6±14.5 0.6 DBP, mmHg (mean ± SD) 77.5±9.6 76.2±13,1 0.7 HR, bpm (mean ± SD) 60.5±6.2 60.6±7.1 0.9 BMI, kg/m2 (mean ± SD) 28.8±4.1 26.1±10.9 0.4 Fasting glucose, mg/dl (mean ± SD) 136.4±33.6 153.6±64.7 0.3 HBA1C, % (mean ± SD) 6.8±1.2 7.2±1.6 0.4 LDL-c, mg/dl (mean ± SD) 77.8±29.0 84.7±28.6 0.5

Results

CR seems to be an effective adjuvant treatment in RA, increasing ischemia and angina threshold, improving physical performance.

Acknowledgement/Funding

FAPESP